The Role of theMTHFRC677T Polymorphism in Methotrexate-Induced Toxicity in Pediatric Osteosarcoma Patients
- 8 June 2017
- journal article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 18 (8) , 787-795
Abstract
Aim: Osteosarcoma patients receive high doses of methotrexate (MTX). However, pharmacogenetic information remains limited and has mainly been investigated in leukemia so far. Patients & methods: We investigated the link between the MTHFR C677T genotype, toxicity levels (mucositis, MTX plasma level, hematological toxicity and hepatotoxicity) and survival of 48 pediatric osteosarcoma patients. Results: The TT genotype did not show more toxicity compared with the CC/CT genotype. However, plasma MTX levels were related with mucositis, but not with hematological toxicity, nor hepatotoxicity. Survival rates did not differ between homozygous and non-homozygous patients. Yet, homozygous patients had higher relapse risk. Conclusion: The MTHFR C667T polymorphism is not predictive for toxicity or overall survival, but could be used for relapse risk stratification.Keywords
Funding Information
- Kinderkankerfonds Leuven
- Kinderkankerfonds vzw
This publication has 28 references indexed in Scilit:
- Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232Journal of Clinical Oncology, 2016
- Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?Expert Opinion on Drug Metabolism & Toxicology, 2015
- Methylenetetrahydrofolate reductase C677T and overall survival in pediatric acute lymphoblastic leukemia: a systematic reviewLeukemia & Lymphoma, 2013
- Advances in individual prediction of methotrexate toxicity: a reviewBritish Journal of Haematology, 2009
- MTHFR polymorphisms’ influence on outcome and toxicity in acute lymphoblastic leukemia patientsLeukemia Research, 2007
- Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphomaJournal of Human Genetics, 2006
- Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genotypes and Risk of Acute Graft-versus-Host Disease Following Hematopoietic Cell Transplantation for Chronic Myelogenous LeukemiaTransplantation and Cellular Therapy, 2006
- Predictors of Oral Mucositis in Patients Receiving Hematopoietic Cell Transplants for Chronic Myelogenous LeukemiaJournal of Clinical Oncology, 2004
- Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemiaThe Pharmacogenomics Journal, 2003
- A Second Genetic Polymorphism in Methylenetetrahydrofolate Reductase (MTHFR) Associated with Decreased Enzyme ActivityMolecular Genetics and Metabolism, 1998